A phase III, multicenter, international, randomized, double-blinded, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with XubixTM (sibrafiban; Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome
Grant Data
Project Title
A phase III, multicenter, international, randomized, double-blinded, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with XubixTM (sibrafiban; Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome
Principal Investigator
Dr Ho, David Sai Wah
(Principal Investigator (PI))
Co-Investigator(s)
Professor Lau Chu Pak
(Co-Investigator)
Duration
4
Start Date
1999-05-01
Amount
250000
Conference Title
A phase III, multicenter, international, randomized, double-blinded, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with XubixTM (sibrafiban; Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome
Presentation Title
Keywords
Acute Coronary Syndrome, XubixTM
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
N/A
Grant Type
Other Funding Scheme
Funding Year
1998
Status
Completed
Objectives
To compare the efficacy of long-term sibrafiban therapy in two regimens (high-dose sibrafiban; low-dose sibrafiban plus aspirin) to that of long-term aspirin therapy in preventing the independent occurrence of death, myocardial infarction or (re)infarction, severe recurrent ischemia, stroke, reversible coronary ischemia, coronary revascularization, and rehospitalization; to collect pharmacoeconomic data for patients taking sibrafiban and patients taking aspirin